Price alert —
Sign in to get a one-time email the moment JAZZ crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · JAZZ
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1.1B | $0.3B | $0.3B | $0.4B | 27.4% | 31.5% |
| 2025-12-31 | $1.2B | $0.2B | $0.3B | $0.3B | 17.0% | 21.2% |
| 2025-09-30 | $1.1B | $0.3B | $0.1B | $0.4B | 22.3% | 8.9% |
| 2025-06-30 | $1.0B | $-0.7B | $0.2B | $0.1B | -68.7% | 20.9% |
| 2025-03-31 | $0.9B | $-0.1B | $-0.1B | $0.4B | -10.3% | -6.2% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare JAZZ vs peers
Line JAZZ up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with JAZZ
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-05 | 6.34 | 4.66 | +36.2% | +7.7% |
| 2026-02-24 | 6.64 | 6.51 | +2.0% | +13.2% |
| 2025-11-05 | 8.13 | 5.85 | +39.0% | -2.3% |
| 2025-08-05 | -8.25 | -6.25 | -32.1% | -6.4% |
| 2025-05-06 | 1.68 | 4.66 | -63.9% | -8.8% |
| 2025-02-25 | 6.60 | 5.81 | +13.6% | +3.2% |
| 2024-11-06 | 6.61 | 5.50 | +20.2% | +6.8% |
| 2024-07-31 | 5.30 | 4.78 | +10.8% | +3.8% |
| 2024-05-01 | 2.68 | 4.18 | -35.9% | -0.9% |
| 2024-02-28 | 5.02 | 5.18 | -3.2% | -8.3% |
| 2023-11-08 | 4.84 | 4.93 | -1.9% | -9.1% |
| 2023-08-09 | 4.51 | 4.43 | +1.8% | +1.6% |
| 2023-05-10 | 3.95 | 4.22 | -6.4% | +0.4% |
| 2023-03-01 | -0.07 | 1.12 | -106.3% | +2.7% |
| 2022-11-09 | 5.17 | 4.67 | +10.6% | +7.1% |
| 2022-08-03 | 4.30 | 4.19 | +2.5% | -0.3% |
| 2022-05-04 | 3.73 | 3.89 | -4.1% | -2.7% |
| 2022-03-01 | 4.21 | 3.64 | +15.6% | +12.1% |
| 2021-11-09 | 4.20 | 3.31 | +26.7% | +3.3% |
| 2021-08-03 | 3.90 | 3.45 | +13.2% | -10.5% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| JAZZ ★ | $15B | 2045.8 | 9.5 | 3.5 | 8.9 | 3.4 | 91.5% | 19.1% | — | 8.66% |
| LLY | — | 41.1 | 25.7 | — | 29.3 | — | 82.8% | 55.5% | 169.9% | — |
| UNH | $391B | 32.4 | 19.2 | 0.9 | 17.5 | 3.7 | 19.5% | 0.4% | 61.5% | 5.82% |
| JNJ | $600B | 29.0 | 19.4 | 6.1 | 18.1 | 7.4 | 68.1% | 6.6% | -1.0% | — |
| MRK | — | 35.6 | 13.1 | — | 11.9 | 6.8 | 76.7% | 4.9% | — | — |
| ABBV | $451B | 124.6 | 15.7 | 7.2 | 17.1 | -67.8 | 72.0% | 12.4% | -46.2% | 4.61% |
| PFE | $142B | 19.3 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.71% |
| TMO | $192B | 28.4 | 19.0 | — | 20.9 | 3.7 | 40.9% | 6.2% | 11.3% | 2.87% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 41.42%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 5,591,700 | 8.90% |
| Vanguard Portfolio Management LLC | 2,983,242 | 4.75% |
| Capital World Investors | 2,673,376 | 4.26% |
| Vanguard Capital Management LLC | 2,648,333 | 4.22% |
| LSV Asset Management | 2,386,840 | 3.80% |
| FMR, LLC | 2,275,762 | 3.62% |
| Franklin Resources, Inc. | 1,958,940 | 3.12% |
| Dimensional Fund Advisors LP | 1,895,215 | 3.02% |
| State Street Corporation | 1,891,646 | 3.01% |
| EcoR1 Capital, LLC | 1,706,469 | 2.72% |
Insider activity · 90d
0 buys / 6 sells · ratio 0.0 · Finnhub
- COZADD BRUCE C SELL 366,682 @ $240.47
- Johnson Philip L F 56,431 @ $237.72
- Pearce Samantha F 47,911 @ $237.72
- Patil Neena M F 48,871 @ $237.72
- Iannone Robert F 85,107 @ $237.72
- GALA RENEE D F 147,361 @ $237.72
- Smith Mark Douglas SELL 9,680 @ $230.55
- Patil Neena M SELL 51,549 @ $231.83
- GALA RENEE D G 152,196
- COZADD BRUCE C SELL 372,682 @ $235.12
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 4 | 2026-07-06 | PRIMARY DOCUMENT | view · |
| 4 | 2026-07-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-07-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-07-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-07-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-07-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-17 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-12 | PRIMARY DOCUMENT | view · |
| DEF 14A | 2026-06-08 | DEF 14A | view · |
| 4 | 2026-06-05 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-03 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-01 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-01 | PRIMARY DOCUMENT | view · |
| 4 | 2026-06-01 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-05-29 | 8-K | view · |
| 4 | 2026-05-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-27 | PRIMARY DOCUMENT | view · |
| 4 | 2026-05-05 | PRIMARY DOCUMENT | view · |
| 10-Q | 2026-05-05 | 10-Q | view · |
| 8-K | 2026-05-05 | 8-K | view · |
| 4 | 2026-04-03 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-09 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-09 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-09 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-09 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-09 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-09 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-09 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-09 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-04 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 4 | 2026-03-02 | PRIMARY DOCUMENT | view · |
| 10-K | 2026-02-24 | 10-K | view · |
| 8-K | 2026-02-24 | 8-K | view · |
| 4 | 2026-01-21 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-21 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-21 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-21 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-21 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-21 | PRIMARY DOCUMENT | view · |
| 4 | 2026-01-21 | PRIMARY DOCUMENT | view · |
| 8-K | 2026-01-12 | 8-K | view · |
| 4 | 2026-01-08 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-11 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-09 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-09 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-04 | PRIMARY DOCUMENT | view · |
| 4 | 2025-12-01 | PRIMARY DOCUMENT | view · |
| 4 | 2025-11-24 | PRIMARY DOCUMENT | view · |
| 4 | 2025-11-21 | PRIMARY DOCUMENT | view · |
| 4 | 2025-11-20 | PRIMARY DOCUMENT | view · |
| 4 | 2025-11-20 | PRIMARY DOCUMENT | view · |
| 4 | 2025-11-20 | PRIMARY DOCUMENT | view · |
About JAZZ
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing…
Options picks · JAZZ
ITM + OTM ideas from the latest scanLoading…
Congress trades · JAZZ
STOCK Act disclosuresLoading…
SEC filings & insiders · JAZZ
EDGAR · liveLoading…
Holders · JAZZ
Institutions & insider activityLoading…